Studies on anti-inflammatory agents. IV. Synthesis and pharmacological properties of 1,5-diarylpyrazoles and related derivatives

Chemical and Pharmaceutical Bulletin

Volumn 45, Issue 6, 1997, Pages 987-995

  Tsuji, Kiyoshi ^a   Nakamura, Katsuya ^a   Konishi, Nobukiyo ^a   Tojo, Takashi ^a   Ochi, Takehiro ^a   Senoh, Hachiro ^a   Matsuo, Masaaki ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

1,5 diarylpyrazole; Anti inflammatory agent; Cyclooxygenase; Structure activity relationship; Synthesis

Indexed keywords

4' ACETYL 2' (2,4 DIFLUOROPHENOXY)METHANESULFONANILIDE; 5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; 5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; ANTIINFLAMMATORY AGENT; CYANIDE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRAZOLE DERIVATIVE;

ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG POTENCY; DRUG SYNTHESIS; DRUG THERAPY; ENZYME ASSAY; HYPERALGESIA; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PAIN THRESHOLD; RAT; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY; YEAST;

EID: 0030860775     PISSN: 00092363     EISSN: None     Source Type: Journal    
DOI: 10.1248/cpb.45.987     Document Type: Article

References (28)

1. Part III: Nakamura K., Tsuji K., Konishi N., Matsuo M., Chem. Pharm. Bull., 41, 2050-2052 (1993).
2. a) Ivey K. J., Am. J. Med., 75 (5A), 53-64 (1983);
3. b) Nanra R. S., ibid., 75 (5A), 70-81 (1983);
4. c) Allison M. C., Howatson A. G., Torrance C. J., Lee F. D., Russell R. I., N. Eng. J. Med., 327, 749-754 (1992).
5. a) Hla T., Neilson K., Proc. Natl. Acad. Sci. U.S.A., 89, 7384-7388 (1992);
6. b) Herschman H. R., Biochim. Biophvs. Acta, 1299, 125-140 (1996).
7. a) Vane J. R., Botting R. M., Inflamm. Res., 44, 1-10 (1995);
8. b) Isakson P., Seibert K., Masferrer J., Salvemini D., Lee L., Needleman P., "Advances in Prostaglandin. Thromboxane, and Leukotriene Research," Vol. 23, ed. by Samuelsson B. et al., Raven Press, Ltd., New York, 1995, pp. 49-54.
9. a) Tsuji K., Nakamura K., Konishi N., Okumura H., Matsuo M., Chem. Pharm. Bull., 40, 2399-2409 (1992);
10. b) Nakamura K., Tsuji K., Konishi N., Okumura H., Matsuo M., ibid., 41, 894-906 (1993).
11. a) Gans K. R., Balles E. A., Galbraith W., Haber S. B., Kerr J. S., Newton R. C., Schmidt W. K., Smith C., Hewes W. E., Ackerman N. R., Pharmacologist, 29, 138 (1987);
12. b) Gans K. R., Galbraith W., Roman R. J., Haber S. B., Kerr J. S., Schmidt W. K., Smith C., Hewes W. E., Ackerman N. R., J. Pharmacol. Exp. Ther., 254, 180-187 (1990).
13. Compound 1 was metabolized to a 5-(methylsulfonyl)thiophene derivative in rats. Compound 1 also showed mutagenicity in a chromosome aberration test conducted by Toxicology Research Laboratories, Fujisawa Pharmaceutical Co., Ltd. (unpublished results).
14. The energy levels and the orbital distributions of HOMO and LUMO, and the torsion angles of the benzene rings of the most stable conformer of 5-bromo-3-(4-acetylphenyl)-2-(4-fluorophenyl)thiophene (38) and that of 3-bromo-5-(4-acetylphenyl)-1-(4-fluorophenyl)pyrazole (39) were calculated by the MNDO method: e.g., the torsion angle of the 4-acetylphenyl ring was +77.7° (38) and +79.1° (39) and that of the 4-fluorophenyl ring was +77.4° (38) and +77.3° (39), respectively.
15. Appleton R. A., Burford S. C., Hardern D. N., Wilkinson D., Eur. Patent 178035 (1986) [Chem. Abstr., 105, 42796f (1986)].
16. The production of the by-product 15 was suppressed when the reaction was conducted in AcOH.
17. Matsuo M., Tsuji K., Konishi N., Nakamura K., Eur. Patent 418845 (1991) [Chem. Abstr., 115, 71593z (1991)].
18. Vorbrueggen H., Schwarz N., Eur. Patent 59156 (1982) [Chem. Abstr., 98, 53895a (1983)].
19. a) Haber S. B., Eur. Patent 87629 (1983) [Chem. Abstr., 100, 22571x (1984)];
20. b) Cherkofsky S. C., U.S. Patent 4302461 (1981) [Chem. Abstr., 96, 104081a (1982)].
21. Manuscript in preparation.
22. COX-2 inhibitors having a sulfonamide group were recently reported: a) Li J. J., Anderson G. D., Burton E. G., Cogburn J. N., Collins J. T., Garland D. J., Gregory S. A., Huang H.-C., Isakson P. C., Koboldt C. M., Logusch E. W., Norton M. B., Perkins W. E., Reinhard E. J., Seibert K., Veenhuizen A. W., Zhang Y., Reitz D. B., J. Med. Chem., 38, 4570-4578 (1995); b) Leblanc Y., Gauthier J. Y., Ethier D., Guay J., Mancini J., Riendeau D., Tagari P., Vickers P., Wong E., Prasit P., Bioorg. Med. Chem. Lett., 5, 2123-2128 (1995).
23. COX-2 inhibitors having a sulfonamide group were recently reported: a) Li J. J., Anderson G. D., Burton E. G., Cogburn J. N., Collins J. T., Garland D. J., Gregory S. A., Huang H.-C., Isakson P. C., Koboldt C. M., Logusch E. W., Norton M. B., Perkins W. E., Reinhard E. J., Seibert K., Veenhuizen A. W., Zhang Y., Reitz D. B., J. Med. Chem., 38, 4570-4578 (1995); b) Leblanc Y., Gauthier J. Y., Ethier D., Guay J., Mancini J., Riendeau D., Tagari P., Vickers P., Wong E., Prasit P., Bioorg. Med. Chem. Lett., 5, 2123-2128 (1995).
24. COX-1 inhibition at 100 μM: 0% (33), 8% (37); COX-2 inhibition at 100 μM: 19% (33), 49% (37).
25. This product was used for the next step in the synthesis without further purification.
26. Tomisawa K., Kameo K., Matsunaga T., Saito S., Hosoda K., Asami Y., Sota K., Chem. Pharm. Bull., 33, 2386-2394 (1985).
27. Matsuo M., Tsuji K., Ogino T., Konishi N., Eur. Patent 554829 (1993) [Chem. Abstr., 120, 8589r (1994)].
28. Supplied by Exploratory Research Laboratories, Fujisawa Pharmaceutical Co., Ltd. (Tsukuba, Ibaraki).